Intensive care unit-related fluconazole use in Spain and Germany: Patient characteristics and outcomes of a prospective multicenter longitudinal observational study

Infection and Drug Resistance

Volumn 6, Issue , 2013, Pages 15-25

  Wissing, Heimo ^a   Ballus, Jose ^b   Bingold, Tobias M ^a   Nocea, Gonzalo ^c   Krobot, Karl J ^d   Kaskel, Peter ^d   Kumar, Ritesh N ^e   Mavros, Panagiotis ^e  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c Medical affairs Merck sharp and Dohme ltd   (Spain)

^d MSD Sharp and Dohme GmbH   (Germany)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antifungal agents; Candida; Fungal infection; Therapy

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE;

ADULT; AGED; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG UTILIZATION; FEMALE; GERMANY; HUMAN; INFECTION PREVENTION; INTENSIVE CARE; LENGTH OF STAY; LOADING DRUG DOSE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; SPAIN; UNSPECIFIED SIDE EFFECT;

EID: 84873375853     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: 10.2147/IDR.S38945     Document Type: Article

References (41)

1. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med. 2006;34(3):857-863.
2. Kett DH, Azoulay E, Echeverria PM, Vincent JL; Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med. 2011;39(4):665-670.
3. Lipsett PA. Surgical critical care: fungal infections in surgical patients. Crit Care Med. 34(Suppl 9):S215-S224.
4. Flanagan PG, Barnes RA. Fungal infection in the intensive care unit. J Hosp Infect. 1998;38(3):163-177.
5. Alvarez-Lerma F, Nolla-Salas J, León C, et al; EPCAN Study Group. Candiduria in critically ill patients admitted to intensive care medical units. Intensive Care Med. 2003;29(7):1069-1076.
6. Borg-von Zepelin M, Kunz L, Rüchel R, Reichard U, Weig M, Gross U. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. J Antimicrob Chemother. 2007;60(2):424-428.
7. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20(1):133-163.
8. Bassetti M, Righi E, Costa A, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis. 2006;6:21.
9. Leroy O, Gangneux JP, Montravers P, et al; AmarCand Study Group. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med. 2009;37(5): 1612-1618.
10. Tortorano AM, Caspani L, Rigoni AL, Biraghi E, Sicignano A, Viviani MA. Candidosis in the intensive care unit: a 20-year survey. J Hosp Infect. 2004;57(1):8-13.
11. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43(1):25-31.
12. Charlier C, Hart E, Lefort A, et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother. 2006;57(3):384-410.
13. Lichtenstern C, Geiss HK, Böttinger BW, Weigand MA. Antimykotische Therapie in der Intensivmedizin [Antimycotic therapy in the intensive care unit]. Intensivmed.up2date. 2007;3:21-40. German.
14. Ullmann AJ, Sanz MA, Tramarin A, et al; Longitudinal Evaluation of Antifungal Drugs (LEAD I) Investigators. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis. 2006;43(4):e29-e38.
15. Fischer MA, Winkelmayer WC, Rubin RH, Avorn J. The hepatotoxicity of antifungal medications in bone marrow transplant recipients. Clin Infect Dis. 2005;41(3):301-307.
16. Kauffman CA, Carver PL. Use of azoles for systemic antifungal therapy. Adv Pharmacol. 1997;39:143-189.
17. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med. 1999;27(6):1066-1072.
18. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med. 2002;28(12):1708-1717.
19. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg. 2001;233(4):542-548.
20. Schuster MG, Edwards JE Jr, Sobel JD, et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med. 2008;149(2):83-90.
21. Rex JH, Pappas PG, Karchmer AW, et al; National Institute of Allergy and Infectious Diseases Mycoses Study Group. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis. 2003;36(10):1221-1228.
22. Montravers P, Jabbour K. Clinical consequences of resistant Candida infections in intensive care. Int J Antimicrob Agents. 2006;27(1):1-6.
23. World Medical Association (WMA). WMA Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Ferney-Voltaire: WMA; 2008. Available from: http://www.wma.net/en/30publications/10policies/b3/17c.pdf. Accessed December 2, 2012.
24. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guideline for Good Clinical Practice. E6(R1). June 10. Geneva: ICH; 1996. Available from: http://private.ich.org/LOB/media/MEDIA482.pdf. Accessed December 2, 2012.
25. Vazquez JA, Sanchez V, Dmuchowski C, Dembry LM, Sobel JD, Zervos MJ. Nosocomial acquisition of Candida albicans: an epidemiologic study. J Infect Dis. 1993;168(1):195-201.
26. Borzotta AP, Beardsley K. Candida infections in critically ill trauma patients: a retrospective case-control study. Arch Surg. 1999;134(6):657-665.
27. De Waele JJ, Vogelaers D, Blot S, Colardyn F. Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. Clin Infect Dis. 2003;37(2):208-213.
28. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med. 1999;27(5):887-892.
29. Vincent JL, Anaissie E, Bruining H, et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med. 1998;24(3):206-216.
30. Nolla-Salas J, Sitges-Serra A, León-Gil C, et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med. 1997;23(1):23-30.
31. Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med. 2005;33(9):1928-1935.
32. Meersseman W, Van Wijngaerden E. Invasive aspergillosis in the ICU: an emerging disease. Intensive Care Med. 2007;33(10): 1679-1681.
33. Sobel JD, Rex JH. Invasive candidiasis: turning risk into a practical prevention policy? Clin Infect Dis. 2001;33:187-189. doi: 10.1086/321812.
34. Pappas PG, Kauffman CA, Andes D, et al; Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503-535.
35. Denning DW. Management of deep Candida infection in surgical and intensive care unit patients. Intensive Care Med. 1994;20(7):522-528.
36. Cornely OA, Bassetti M, Calandra T, et al; ESCMID Fungal Infection Study Group. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(Suppl 7):19-37.
37. Kullberg BJ, Oude Lashof AM. Epidemiology of opportunistic invasive mycoses. Eur J Med Res. 2002;7(5):183-191.
38. Pappas PG, Rex JH, Lee J, et al; NIAID Mycoses Study Group. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003;37(5):634-643.
39. Pfaller MA, Jones RN, Doern GV, et al. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis. 1999;35(1):19-25.
40. Garnacho-Montero J, Díaz-Martín A, García-Cabrera E, et al. Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother. 2010;54(8):3149-3154.
41. Kam LW, Lin JD. Management of systemic candidal infections in the intensive care unit. Am Syst Health Care Pharm. 2002;59(1):33-41.